Disruptive Pharma agrees to sell GTX platform, keeps royalty rights

Disruptive Pharma AB (publ) agreed to sell its GTX platform to a wholly owned subsidiary of Aurelia Invest AB, with modest upfront cash plus retained future milestone and royalty rights.